Navigation Links
Alexza Reports 2008 Third Quarter Financial Results and Updates Development of Product Candidates
Date:11/6/2008

The trial was an in-clinic, multicenter, randomized, double-blind, placebo-controlled study and tested AZ-004 at two dose levels, 5 and 10 mg. Patients could receive up to 3 doses of study drug in a 24-hour period, depending on their clinical status. Patients eligible for the study include those who are admitted through an emergency department and those who are already in-patients in a hospital setting, as long as they had acute agitation at the time of patient randomization. This study was the first AZ-004 study enrolling bipolar disorder patients.

In September 2008, the Company announced positive results from its first Phase 3 clinical trial of AZ-004 in schizophrenic patients with acute agitation. Both the 5 mg and the 10 mg doses of AZ-004 met the primary and secondary endpoints of the study. The administration of AZ-004 was generally safe and well tolerated in this patient population.

Alexza has completed five clinical trials with AZ-004, enrolling more than 800 patients to date, and has announced positive results from the first four of these studies. These four studies include a 50 subject Phase 1 study in healthy volunteers, a 129 patient Phase 2 study in agitated schizophrenic patients, a 32 patient multiple-dose tolerability and pharmacokinetic study in non-agitated schizophrenic patients, and a 344 patient Phase 3 study in schizophrenic patients with acute agitation. Alexza completed an end-of-Phase 2 meeting with the FDA for AZ-004 in September 2007 and believes it has a clear understanding of the development requirements for filing an NDA for AZ-004.

AZ-004 has been licensed to Symphony Allegro, Inc., or Symphony Allegro, and the Company has the right to repurchase all rights to this product candidate.

-- AZ-001 (Staccato prochlorperazine). Alexza is developing AZ-001 to treat patients suffering from acute migraine headaches. During the third quarter of 2008, Alexza conducted an end-of-Phase 2 meeting with the FDA. The Company
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Alexza to Initiate the First Phase 3 Trial for AZ-004 (Staccato(R) Loxapine) in Late Q1 2008
2. Alexza and Autoliv Announce Commercial Manufacturing and Supply Agreement for Heat Packages Used in Single-Dose Staccato(R) System
3. Alexzas Corporate Presentation to be Webcast at the Cowen & Company 28th Annual Health Care Conference
4. Alexza Secures $50 Million Committed Equity Financing Facility With Azimuth Opportunity, Ltd.
5. Alexza to Webcast Investor and Analyst Day Presentations
6. Alexzas Corporate Presentation to be Webcast at the Seventh Annual JMP Securities Research Conference and the 2008 Citi Investment Research Global Healthcare Conference
7. Carlos A. Parra Joins Alexza Pharmaceuticals as Vice President, Quality
8. Jeffrey S. Williams Rejoins Alexza Pharmaceuticals as President, Alexza Singapore Pte. Ltd.
9. Anthony Clarke, PhD Joins Alexza Pharmaceuticals as Vice President, International Development Operations
10. Alexza to Announce 2008 Third Quarter Financial Results and Update Its Clinical Pipeline on Thursday, November 6, 2008
11. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... 04, 2015 Takeda Pharmaceuticals Corp. has ... settle thousands of Actos lawsuits ( http://www.theactoslawsuitcenter.com/ ) ... risk that a patient will develop bladder cancer. According ... 95% of those eligible for the Actos settlement accept ... cancer cases currently pending in courts around the country, ...
(Date:5/4/2015)... 04, 2015 “ LiveSchool ” was ... which takes a look at the latest and coolest ... Joe Toohey, the host of AppWatch and technology expert, ... this application allows teachers to reward students with good ... realize, especially in the classroom. And the good ...
(Date:5/4/2015)... Jacksonville, Fla. (PRWEB) May 04, 2015 ... American Heart Association/American Stroke Association’s Get With The ... the Target: Stroke Honor Roll. The award recognizes ... stroke patients receive the most appropriate treatment according ... latest scientific evidence. , To receive the Gold ...
(Date:5/4/2015)... Ticket Down is a reputable source for authentic ... While the World Cup is the most known soccer ... the International Champions Cup is one of the biggest tournaments ... record for soccer in the United States set when Manchester ... University of Michigan. This year, the defending champion Manchester United ...
(Date:5/4/2015)... May 04, 2015 Ticket Down is a ... Colonial Life Arena in Columbia, South Carolina. Fans ... of his “Out There” tour which originally kicked off in ... is North America and the legendary performer recently announced that ... Wells Fargo Arena on June 21st, in Charlottesville, VA at ...
Breaking Medicine News(10 mins):Health News:Actos Lawsuit Settlement: Takeda Pharmaceutical Co. to Pay As Much As $2.4 Billion to Resolve Claims Alleging Actos Causes Bladder Cancer 2Health News:Actos Lawsuit Settlement: Takeda Pharmaceutical Co. to Pay As Much As $2.4 Billion to Resolve Claims Alleging Actos Causes Bladder Cancer 3Health News:An Application for Teachers to Reward Students with Good Behavior Was Featured on NewsWatch Television 2Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 2Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 3Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 4Health News:Cheap 2015 International Champions Cup (ICC) Tickets: Ticket Down Slashes Ticket Prices on International Champions Cup (ICC) Presale Tickets 2Health News:Cheap 2015 International Champions Cup (ICC) Tickets: Ticket Down Slashes Ticket Prices on International Champions Cup (ICC) Presale Tickets 3Health News:Cheap 2015 International Champions Cup (ICC) Tickets: Ticket Down Slashes Ticket Prices on International Champions Cup (ICC) Presale Tickets 4Health News:Paul McCartney Tickets at Colonial Life Arena in Columbia, SC: Ticket Down Slashes Paul McCartney Ticket Prices in Columbia, South Carolina at Colonial Life Arena 2
... for Drug and Social Policy Research (CDSPR) has been awarded ... to study the long-term consequences of adolescent gang membership among ... next four years. , "This is a follow-up to ... members in west San Antonio," said Avelardo Valdez, principal investigator ...
... Feb. 12 Harris Corporation,(NYSE: ... technology,company, has been awarded a ten-year contract ... system, to provide network,management and IT services ... Health First Infrastructure Services (HFIS) contract includes,software ...
... with acute osteomyelitis--a bacterial bone infection--an early changeover from ... as effective as continuing the IV therapy, according to ... are more convenient for children and families, and avoid ... complications from using central catheters, such as infections or ...
... play a key role in the prevention and treatment ... , Endothelial cells line the blood vessels and are ... function. , Researchers at the Centenary Institute have ... endothelial cells. , Professor Jenny Gamble, Head ...
... Inc., the leader in,the development of devices for ... the first series of patients have been successfully,treated ... Hospital, Nieuwegein,Utrecht, Netherlands. The MitraClip(R) system is the ... which provides a non-surgical,mitral valve repair option for ...
... by using the benefits of the world,s largest member discount ... American jobs were lost in 2008, and many of those ... more also start the New Year in dire financial situations; ... in household budgets. Unfortunately, some people may consider cuts in ...
Cached Medicine News:Health News:Gang researchers at UH examine health, consequences of long-term gang 2Health News:Health First Healthcare System Awards Harris Corporation Enterprise-wide Network Management and IT Services Contract 2Health News:Health First Healthcare System Awards Harris Corporation Enterprise-wide Network Management and IT Services Contract 3Health News:Early switch from IV to oral meds is effective for children with acute bone infection 2Health News:Deciphering the body's healing secrets 2Health News:First Dutch Patients Treated With the Percutaneous MitraClip(R) System 2Health News:First Dutch Patients Treated With the Percutaneous MitraClip(R) System 3Health News:During Tough Economic Times Remember Your Health - Save With Your AAA Membership on Necessities From Prescriptions to Eyeglasses 2Health News:During Tough Economic Times Remember Your Health - Save With Your AAA Membership on Necessities From Prescriptions to Eyeglasses 3
(Date:5/4/2015)... WHIPPANY, N.J. , May 4, 2015 ... agreement with Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ) ... clinical development for the prevention of thrombosis. Under the ... in areas of high unmet medical need. As ... evaluate the therapeutic profile of ISIS-FXI Rx in ...
(Date:5/4/2015)... 2015   HeartWare International, Inc . (NASDAQ: HTWR ... technologies that are revolutionizing the treatment of advanced heart failure, ... is scheduled to present at the Bank of America Merrill ... on Thursday, May 14, 2015, at 10:00 a.m. ... the Company,s presentation at the conference will be available via ...
(Date:5/4/2015)... , May 4, 2015  Isis Pharmaceuticals, Inc. (NASDAQ: ... agreement with Bayer HealthCare (Bayer) to develop and commercialize ... the terms of the agreement, Isis is eligible to ... an immediate $100 million up-front payment and a $55 ... Phase 2 study in patients with compromised kidney function. ...
Breaking Medicine Technology:Bayer Licenses Investigational ISIS FXI(Rx) from Isis Pharmaceuticals to Develop and Commercialize for the Prevention of Thrombosis 2Bayer Licenses Investigational ISIS FXI(Rx) from Isis Pharmaceuticals to Develop and Commercialize for the Prevention of Thrombosis 3HeartWare Presentation At Bank Of America Merrill Lynch 2015 Health Care Conference To Be Webcast 2Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 2Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 3Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 4Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 5
The Programmable MP-3500P-F Power Supply can be applied for any Microfluidic application....
MP-250N and 300N is a new style power supply. It is a versatile microprocessor power supply for horizontal or vertical gel electrophoresis. The unit is programmable and offers constant voltage and co...
Handy 100V Power Supply is Low-cost, compact and lightweight. Easy to operate - either 50 or 100 VDC is selectable as the output voltage. These voltages are sufficient for ordinary electrophoresis....
... Dual Power is a microprocessor-controlled programmable ... high voltage/low current and high current/low ... current section is ideal for sample ... sequencing applications. The low voltage/high current ...
Medicine Products: